<Li> Whether the cancer will ever need treatment: Diagnosis of a cancer in a person who will never be harmed by the cancer is called overdiagnosis . Overdiagnosis is most common among older people with slow - growing cancers . Concerns about overdiagnosis are common for breast and prostate cancer . </Li> <Li> Whether the test is acceptable to the patients: If a screening test is too burdensome, such as requiring too much time, too much pain, or culturally unacceptable behaviors, then people will refuse to participate . </Li> <Li> Cost of the test: Some expert bodies, such as the U.S. Preventative Services Task Force, completely ignore the question of money . Most, however, include a cost - effectiveness analysis that, all else being equal, favors less expensive tests over more expensive tests, and attempt to balance the cost of the screening program against the benefits of using those funds for other health programs . These analyses usually include the total cost of the screening program to the healthcare system, such as ordering the test, performing the test, reporting the results, and biopsies for suspicious results, but not usually the costs to the individual, such as for time taken away from employment . </Li> <Li> The extent to which a cancer is treatable: if a person has a low life expectancy or otherwise is in the end stages of a chronic condition, then such a patient may have a better life by ignoring the cancer even if one were found . If the diagnosis of cancer would not result in a change in care then cancer screening would not likely result in a positive outcome . Overdiagnosis in this case occurs, for example, in patients with end - stage renal disease and organizations recommend against cancer screening for such patients . </Li>

Explain the role immunochemical screening in detection of various cancer types